Lao People's Democratic RepublicTuberculosis profile
Population  2015 6.8 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.3 (2–5.1) 49 (29–75)
Mortality (HIV+TB only) 0.25 (0.14–0.39) 3.6 (2–5.7)
Incidence  (includes HIV+TB) 12 (8–18) 182 (118–260)
Incidence (HIV+TB only) 0.59 (0.36–0.88) 8.7 (5.3–13)
Incidence (MDR/RR-TB)** 0.76 (0.39–1.1) 11 (5.7–16)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.69 (<0.01–1.4) 3.7 (1.1–6.2) 4.4 (1.2–7.5)
Males 1.5 (0.86–2.1) 6.6 (4.4–8.8) 8 (5.2–11)
Total 2.1 (1.4–2.9) 10 (7.4–13) 12 (8–18)
TB case notifications, 2015  
Total cases notified 4 638
Total new and relapse 4 534
          - % tested with rapid diagnostics at time of diagnosis 37%
          - % with known HIV status 90%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 37% (26–57)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.3 (0.16–0.52)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 310 8%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  280
(190–360)
Estimated % of TB cases with MDR/RR-TB 5.2% (3.1–7.3) 28% (25–30)  
% notified tested for rifampicin resistance 36% 40% 1 689
MDR/RR-TB cases tested for resistance to second-line drugs   14
Laboratory-confirmed cases MDR/RR-TB: 33, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 33, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 86% 4 198
Previously treated cases, excluding relapse, registered in 2014 61% 23
HIV-positive TB cases, all types, registered in 2014 57% 292
MDR/RR-TB cases started on second-line treatment in 2013 71% 7
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 13%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
42% (38–46)
TB financing, 2016  
National TB budget (US$ millions) 2.9
Funding source: 12% domestic, 88% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data